Therapies of Interest in Combatting COVID-19

Chanprit Singh

doi:10.26440/IHRJ/0406.09328

Chanprit Singh

DOI: https://doi.org/10.26440/IHRJ/0406.09328

Keywords: Coronavirus, COVID-19, SARS-CoV-2

Abstract

By the end of year 2019, the coronavirus infection originated in China and in a short span of time entangled the whole world. This rapidly expanding coronavirus 2019 (also called COVID-19, 2019-nCoV or SARS-CoV-2) infected around eight lac people and resulted in more than 38000 deaths worldwide by 1st April 2020. Elderly people, immunocompromised subjects and those with comorbidities were found to be affected more often. This review focuses on the current knowledge related to therapies of interest for tackling COVID-19 which include drugs with antiviral activity that have been regularly used in other diseases and other drugs which don’t fall under antiviral category but are gaining popularity in the current situation for their possible and potential effectiveness against coronavirus. Although progress has been made in determining potential of these therapeutic alternatives, long term safety-efficacy studies of these agents in COVID-19 infected subjects are required.

Downloads

Download data is not yet available.

Author Biography

Chanprit Singh

BDS, PG student, School of Community Studies, Bow Valley College, 345, 6^th Avenue SE, Calgary, AB T2G 4V1, Canada

References

Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020; 38(1): 10-8.

Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet Lond Engl. 2020;395(10223): 470-3.

Singhal T. A review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020; 87(4): 281-6.

Wujtewicz M, Dylczyk-Sommer A, Aszkiełowicz A, Zdanowski S, Piwowarczyk S, Owczuk R. COVID-19- what should anaethesiologists and intensivists know about it?. Anaesthesiol Intensive Ther. 2020; 52(1): 34-41.

Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study. J Infect. 2020.

Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69 cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020.

Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020; 14(1): 64-8.

Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak: an update on the status. A thousand Med Res. 2020; 7(1): 11.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3): 269-71.

Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: an overview. J Chin Med Assoc. 2020; 83(3): 217-20.

Holshue ML, De Bolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020; 382(10): 929-36.

Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020; 19(3):149-50.

Yao T-T, Qian J-D, Zhu W-Y, Wang Y, Wang G-Q. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus: a possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020.

Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of Lopinavir/Ritonavir for the treatment of COVID-19 infected Pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35(6): e79.

Bhatnagar T, Murhekar MV, Soneja M, Gupta N, Giri S, Wig N, et al. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: protocol for restricted public health emergency use. Indian J Med Res. 2020.

Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14(1): 58-60.

Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018; 153: 85-94.

Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017; 93(7): 449-63.

Baron SA, Devaux C, Colson P, Raoult D, Rolain J-M. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?. Int J Antimicrob Agents. 2020; 105944.

Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, et al. Glycopeptide antibiotics potently inhibit Cathepsin L in the late endosome/ lysosome and block the entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). J Biol Chem. 2016; 291(17): 9218-32.

Zhang J, Ma X, Yu F, Liu J, Zou F, Pan T, et al. Teicoplanin potently blocks the cell entry of 2019-nCoV. BioRxiv. 2020.

Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020; 105938.

Wang P, Cheng Y. Increasing host cellular Receptor-Angiotensin-Converting Enzyme 2 (ACE2) expression by Coronavirus may facilitate 2019-nCoV Infection. BioRxiv. 2020.

Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020.

Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis. 2001; 184(6): 770-6.

Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against Coronavirus Disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 2020; 105945.

Zhou D, Dai S-M, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020.

Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 105949.